Coinbase CEO Brian Armstrong’s NewLimit Secures $130M to Pioneer Age-Reversing Therapies
NewLimit Raises $130 Million in Series B Funding
NewLimit, a forward-thinking startup focused on extending healthy lifespans, has successfully secured $130 million in its Series B funding round. The investment was led by Kleiner Perkins, with significant contributions from notable investors such as Nat Friedman, Daniel Gross, and Khosla Ventures. Returning backers including Founders Fund, Dimension Capital, Elad Gil, Garry Tan, Patrick Collison, and others also participated, underscoring strong confidence in the company's vision and potential.
Strong Growth Following Series A Success
This latest fundraise comes two years after NewLimit raised $40 million in its Series A round, highlighting the company’s impressive growth trajectory. The substantial increase in funding reflects the progress NewLimit has made in its mission to enhance longevity through genetic programming of cells. Investors are clearly recognizing the promising advancements and future prospects of the startup in the biotech landscape.
Visionary Founding Team Leads Innovation
Founded over four years ago by Brian Armstrong, CEO of Coinbase, former GV partner Blake Bryers, and stem cell professor Jacob Kimmel, NewLimit boasts a team with exceptional expertise. This dynamic leadership trio brings a blend of industry experience, academic knowledge, and entrepreneurial spirit to drive the company's innovative efforts. Their combined skills have been instrumental in advancing NewLimit’s research and development initiatives.
Breakthroughs in Cell Reprogramming
NewLimit has made significant strides in developing treatments that restore youthful characteristics to aged cells. According to Blake Bryers, the company has discovered three prototype medicines that effectively reprogram liver cells. Lab experiments have demonstrated that this rejuvenation process enhances the cells' ability to process fat and alcohol, making aged liver cells function more like their younger counterparts.
AI-Driven Drug Development
Looking ahead, NewLimit plans to leverage artificial intelligence to accelerate the development of new anti-aging medicines. By utilizing an AI model, the company can run extensive simulations to identify the most promising drug candidates before conducting laboratory tests. This 'lab in a loop' approach not only speeds up the research process but also ensures that resources are focused on the most viable treatments.
Future Steps and Industry Impact
Despite the promising early results, NewLimit remains a few years away from initiating human trials. In the meantime, the company is dedicated to advancing its AI-enhanced drug development pipeline. With significant funding and a robust roadmap, NewLimit is poised to make a substantial impact in the biotech industry, joining other notable startups aimed at increasing human lifespan.
Conclusion
NewLimit's impressive Series B funding round underscores the growing interest and investment in biotechnology solutions aimed at extending healthy human lifespans. With a strong founding team, groundbreaking research in cell reprogramming, and innovative AI-driven methodologies, the company is well-positioned to lead advancements in the anti-aging sector. As NewLimit continues to develop its treatments, it adds to a dynamic field of startups dedicated to enhancing longevity and improving quality of life.
Read the full article here:
techcrunch.com